Third-party reporting says Halozyme secured legal victories against Merck in Europe over its Keytruda subcutaneous patent. The rulings prevent Merck from launching the product in key European markets. The report does not specify the markets or quantify the financial impact.
Key facts
Halozyme secured a legal victory in Europe against Merck regarding Halozyme's Keytruda subcutaneous patent. source
Halozyme's legal victories against Merck regarding the Keytruda subcutaneous patent prevented its launch in key markets. source